vs
ADMA BIOLOGICS, INC.（ADMA）与Shoals Technologies Group, Inc.（SHLS）财务数据对比。点击上方公司名可切换其他公司
Shoals Technologies Group, Inc.的季度营收约是ADMA BIOLOGICS, INC.的1.0倍（$140.6M vs $139.2M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs -0.2%，领先35.7%），Shoals Technologies Group, Inc.同比增速更快（74.9% vs 18.4%），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 19.0%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Shoals科技集团是可再生能源及电动出行领域的电气系统平衡解决方案供应商，核心产品覆盖光伏、储能及充电桩用连接组件，主要服务北美、欧洲、亚太市场的公用事业、工商业及民用客户。
ADMA vs SHLS — 直观对比
营收规模更大
SHLS
是对方的1.0倍
$139.2M
营收增速更快
SHLS
高出56.5%
18.4%
净利率更高
ADMA
高出35.7%
-0.2%
两年增速更快
ADMA
近两年复合增速
19.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $140.6M |
| 净利润 | $49.4M | $-297.0K |
| 毛利率 | 63.8% | 29.2% |
| 营业利润率 | 45.1% | 5.5% |
| 净利率 | 35.5% | -0.2% |
| 营收同比 | 18.4% | 74.9% |
| 净利润同比 | -55.9% | -5.3% |
| 每股收益（稀释后） | $0.20 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMASHLS
| Q1 26 | — | $140.6M | ||
| Q4 25 | $139.2M | $148.3M | ||
| Q3 25 | $134.2M | $135.8M | ||
| Q2 25 | $122.0M | $110.8M | ||
| Q1 25 | $114.8M | $80.4M | ||
| Q4 24 | $117.5M | $107.0M | ||
| Q3 24 | $119.8M | $102.2M | ||
| Q2 24 | $107.2M | $99.2M |
净利润ADMASHLS
| Q1 26 | — | $-297.0K | ||
| Q4 25 | $49.4M | $8.1M | ||
| Q3 25 | $36.4M | $11.9M | ||
| Q2 25 | $34.2M | $13.9M | ||
| Q1 25 | $26.9M | $-282.0K | ||
| Q4 24 | $111.9M | $7.8M | ||
| Q3 24 | $35.9M | $-267.0K | ||
| Q2 24 | $32.1M | $11.8M |
毛利率ADMASHLS
| Q1 26 | — | 29.2% | ||
| Q4 25 | 63.8% | 31.6% | ||
| Q3 25 | 56.3% | 37.0% | ||
| Q2 25 | 55.1% | 37.2% | ||
| Q1 25 | 53.2% | 35.0% | ||
| Q4 24 | 53.9% | 37.6% | ||
| Q3 24 | 49.8% | 24.8% | ||
| Q2 24 | 53.6% | 40.3% |
营业利润率ADMASHLS
| Q1 26 | — | 5.5% | ||
| Q4 25 | 45.1% | 11.7% | ||
| Q3 25 | 38.0% | 13.7% | ||
| Q2 25 | 35.1% | 14.4% | ||
| Q1 25 | 30.4% | 5.4% | ||
| Q4 24 | 32.6% | 15.4% | ||
| Q3 24 | 33.1% | 4.4% | ||
| Q2 24 | 36.6% | 18.7% |
净利率ADMASHLS
| Q1 26 | — | -0.2% | ||
| Q4 25 | 35.5% | 5.5% | ||
| Q3 25 | 27.1% | 8.7% | ||
| Q2 25 | 28.1% | 12.5% | ||
| Q1 25 | 23.4% | -0.4% | ||
| Q4 24 | 95.2% | 7.3% | ||
| Q3 24 | 30.0% | -0.3% | ||
| Q2 24 | 29.9% | 11.9% |
每股收益（稀释后）ADMASHLS
| Q1 26 | — | $0.00 | ||
| Q4 25 | $0.20 | $0.05 | ||
| Q3 25 | $0.15 | $0.07 | ||
| Q2 25 | $0.14 | $0.08 | ||
| Q1 25 | $0.11 | $0.00 | ||
| Q4 24 | $0.45 | $0.04 | ||
| Q3 24 | $0.15 | $0.00 | ||
| Q2 24 | $0.13 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $1.9M |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $601.6M |
| 总资产 | $624.2M | $1.0B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMASHLS
| Q1 26 | — | $1.9M | ||
| Q4 25 | $87.6M | $7.3M | ||
| Q3 25 | $61.4M | $8.6M | ||
| Q2 25 | $90.3M | $4.7M | ||
| Q1 25 | $71.6M | $35.6M | ||
| Q4 24 | $103.1M | $23.5M | ||
| Q3 24 | $86.7M | $11.1M | ||
| Q2 24 | $88.2M | $3.2M |
总债务ADMASHLS
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $141.8M | ||
| Q4 24 | $72.3M | $141.8M | ||
| Q3 24 | — | $141.8M | ||
| Q2 24 | — | $146.8M |
股东权益ADMASHLS
| Q1 26 | — | $601.6M | ||
| Q4 25 | $477.3M | $600.0M | ||
| Q3 25 | $431.2M | $589.6M | ||
| Q2 25 | $398.3M | $575.4M | ||
| Q1 25 | $373.4M | $558.9M | ||
| Q4 24 | $349.0M | $556.8M | ||
| Q3 24 | $231.9M | $545.2M | ||
| Q2 24 | $188.3M | $544.6M |
总资产ADMASHLS
| Q1 26 | — | $1.0B | ||
| Q4 25 | $624.2M | $904.1M | ||
| Q3 25 | $568.7M | $851.8M | ||
| Q2 25 | $558.4M | $795.0M | ||
| Q1 25 | $510.6M | $788.4M | ||
| Q4 24 | $488.7M | $793.1M | ||
| Q3 24 | $390.6M | $801.3M | ||
| Q2 24 | $376.4M | $788.4M |
负债/权益比ADMASHLS
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.25× | ||
| Q4 24 | 0.21× | 0.25× | ||
| Q3 24 | — | 0.26× | ||
| Q2 24 | — | 0.27× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | — |
| 自由现金流经营现金流 - 资本支出 | $34.6M | — |
| 自由现金流率自由现金流/营收 | 24.8% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | — |
8季度趋势，按日历期对齐
经营现金流ADMASHLS
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $-4.1M | ||
| Q3 25 | $13.3M | $19.4M | ||
| Q2 25 | $21.1M | $-13.8M | ||
| Q1 25 | $-19.7M | $15.6M | ||
| Q4 24 | $50.2M | $14.0M | ||
| Q3 24 | $25.0M | $15.7M | ||
| Q2 24 | $45.6M | $37.8M |
自由现金流ADMASHLS
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $-11.3M | ||
| Q3 25 | $-1.1M | $9.0M | ||
| Q2 25 | $18.7M | $-26.0M | ||
| Q1 25 | $-24.4M | $12.3M | ||
| Q4 24 | $47.5M | $12.5M | ||
| Q3 24 | $24.0M | $13.3M | ||
| Q2 24 | $43.6M | $35.8M |
自由现金流率ADMASHLS
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | -7.6% | ||
| Q3 25 | -0.8% | 6.6% | ||
| Q2 25 | 15.3% | -23.5% | ||
| Q1 25 | -21.2% | 15.4% | ||
| Q4 24 | 40.4% | 11.6% | ||
| Q3 24 | 20.0% | 13.0% | ||
| Q2 24 | 40.7% | 36.1% |
资本支出强度ADMASHLS
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 4.8% | ||
| Q3 25 | 10.7% | 7.7% | ||
| Q2 25 | 2.0% | 11.0% | ||
| Q1 25 | 4.1% | 4.0% | ||
| Q4 24 | 2.3% | 1.4% | ||
| Q3 24 | 0.9% | 2.3% | ||
| Q2 24 | 1.9% | 2.0% |
现金转化率ADMASHLS
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | -0.50× | ||
| Q3 25 | 0.36× | 1.63× | ||
| Q2 25 | 0.62× | -1.00× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | 1.79× | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | 3.21× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
SHLS
暂无分部数据
